edited by George Edward Billman
Profiles potential treatment approaches for cardiac arrhythmias!
Filling a gap in the current literature, Novel Therapeutic Targets for Antiarrhythmic Drugs presents the latest treatments for cardiac arrhythmias alongside comprehensive presentations of basic cardiac physiology and pharmacology. It offers both practitioners and researchers a one-stop guide that brings together previously dispersed information.
- comprehensively reviews basic cardiac electrophysiology, the mechanisms responsible for arrhythmias in the setting of ischemia, and basic pharmacology of antiarrhythmic drugs
- addresses safety pharmacology, including the concept of "repolarization reserve," safety challenges, and regulatory issues for the development of novel antiarrhythmic drugs
- describes several novel pharmacological targets for antiarrhythmic drugs, including both ion channel and non-ion channel targets
- describes promising non-pharmacological antiarrhythmic interventions including selective cardiac neural disruption or nerve stimulation, aerobic exercise training, and diet (omega-3 fatty acids)
- Myocardial potassium channels: primary determinants of action potential repolarization
- The "funny" pacemaker current
- Arrhythmia mechanisms in ischemia and infarction
- Antiarrhythmic drug classification
- Repolarization reserve and proarrhythmic risk
- Safety Challenges in the development of novel antiarrhythmic drugs
- Safety Pharmacology and regulatory issues in the development of antiarrhythmic medications.
- Ion channel remodeling and arrhythmias
- Redox modification of ryanodine receptors by heart failure and cardiac arrhythmias: a potential therapeutic target
- Targeting sodium/calcium exchange as an antiarrhythmic strategy
- Calcium/calmodulin-dependent protein kinase II (CaMKII) - Modulation of ion currents and potential role for arrhythmias
- Selective targeting of ventricular potassium channels for arrhythmia suppression: feasible or risible?
- Cardiac sarcolemmal ATP-sensitive potassium channel antagonists: a class of drugs that may selectively target the ischemic myocardium
- Mitochondrial Origin of Ischemia-Reperfusion Arrhythmias: cardiac mitochondria as a novel target for antiarrhythmic drugs
- Cardiac gap junction modulators: a new target for antiarrhythmic drugs
- Novel Pharmacological Targets for the Management of Atrial Fibrillation
- Ultra-rapid delayed rectifier potassium current, IKur: a therapeutic target for atrial arrhythmias
- Effects of endurance exercise training on cardiac autonomic regulation and susceptibility to sudden cardiac death: a non-pharmacological approach for the prevention of ventricular fibrillation
- Dietary Omega-3 fatty acids as a Non-pharmacological Antiarrhythmic Intervention